Efficacy and Safety of Fixed-Dose Combinations of Sitagliptin and Empagliflozin as Add-On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double-Blind, Multi-Centre, Placebo-Contro
5 hours ago
- #clinical trial
- #combination therapy
- #type 2 diabetes
- The study evaluated fixed-dose combinations of sitagliptin (100 mg) with empagliflozin (10 mg or 25 mg) as add-on to metformin in Korean type 2 diabetes patients.
- Both active treatments significantly reduced HbA1c versus placebo at 24 weeks, with differences of -0.54% and -0.61%.
- Improvements were also seen in fasting plasma glucose, body weight, blood pressure, and other parameters, sustained through 52 weeks.
- Safety profiles were favorable with no increased hypoglycemia risk and adverse events similar to placebo.